Year |
Citation |
Score |
2023 |
Tumban E. Bacteriophage Virus-Like Particles: Platforms for Vaccine Design. Methods in Molecular Biology (Clifton, N.J.). 2738: 411-423. PMID 37966612 DOI: 10.1007/978-1-0716-3549-0_24 |
0.356 |
|
2023 |
Kheirvari M, Liu H, Tumban E. Virus-like Particle Vaccines and Platforms for Vaccine Development. Viruses. 15. PMID 37243195 DOI: 10.3390/v15051109 |
0.388 |
|
2021 |
Zhai L, Anderson D, Bruckner E, Tumban E. Novel expression of coat proteins from thermophilic bacteriophage ΦIN93 and evaluation for assembly into virus-like particles. Protein Expression and Purification. 105932. PMID 34214599 DOI: 10.1016/j.pep.2021.105932 |
0.361 |
|
2021 |
Yadav R, Zhai L, Kunda NK, Muttil P, Tumban E. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51. Viruses. 13. PMID 34200586 DOI: 10.3390/v13061113 |
0.386 |
|
2020 |
Basu R, Zhai L, Rosso B, Tumban E. Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus. Vaccine. PMID 32044164 DOI: 10.1016/J.Vaccine.2020.01.091 |
0.447 |
|
2019 |
Yadav R, Zhai L, Tumban E. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? Viruses. 12. PMID 31877975 DOI: 10.3390/V12010018 |
0.509 |
|
2019 |
Tumban E. A Current Update on Human Papillomavirus-Associated Head and Neck Cancers. Viruses. 11: 922. PMID 31600915 DOI: 10.3390/V11100922 |
0.431 |
|
2019 |
Zhai L, Yadav R, Kunda NK, Anderson D, Bruckner E, Miller EK, Basu R, Muttil P, Tumban E. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer. Antiviral Research. PMID 30926288 DOI: 10.1016/J.Antiviral.2019.03.012 |
0.473 |
|
2019 |
Kunda NK, Peabody J, Zhai L, Price DN, Chackerian B, Tumban E, Muttil P. Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9. Human Vaccines & Immunotherapeutics. PMID 30883270 DOI: 10.1080/21645515.2019.1593727 |
0.441 |
|
2018 |
Basu R, Zhai L, Contreras A, Tumban E. Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells. Vaccine. PMID 29395533 DOI: 10.1016/J.Vaccine.2018.01.056 |
0.462 |
|
2017 |
Zhai L, Peabody J, Pang YS, Schiller J, Chackerian B, Tumban E. A novel candidate MS2 phage VLP vaccine displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. Antiviral Research. PMID 28939477 DOI: 10.1016/J.Antiviral.2017.09.012 |
0.483 |
|
2017 |
Peabody J, Muttil P, Chackerian B, Tumban E. Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature. Papillomavirus Research (Amsterdam, Netherlands). 3: 116-120. PMID 28720444 DOI: 10.1016/J.Pvr.2017.03.004 |
0.495 |
|
2016 |
Basu R, Tumban E. Zika Virus on a Spreading Spree: what we now know that was unknown in the 1950's. Virology Journal. 13: 165. PMID 27716242 DOI: 10.1186/S12985-016-0623-2 |
0.423 |
|
2016 |
Zhai L, Tumban E. Gardasil-9: A global survey of projected efficacy. Antiviral Research. 130: 101-9. PMID 27040313 DOI: 10.1016/J.Antiviral.2016.03.016 |
0.442 |
|
2016 |
Saboo S, Tumban E, Peabody J, Wafula D, Peabody DS, Chackerian B, Muttil P. Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus. Molecular Pharmaceutics. 13: 1646-55. PMID 27019231 DOI: 10.1021/Acs.Molpharmaceut.6B00072 |
0.519 |
|
2015 |
Tumban E, Muttil P, Escobar CA, Peabody J, Wafula D, Peabody DS, Chackerian B. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Vaccine. 33: 3346-53. PMID 26003490 DOI: 10.1016/J.Vaccine.2015.05.016 |
0.492 |
|
2014 |
Tyler M, Tumban E, Dziduszko A, Ozbun MA, Peabody DS, Chackerian B. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine. 32: 4267-74. PMID 24962748 DOI: 10.1016/J.Vaccine.2014.06.054 |
0.513 |
|
2014 |
Tyler M, Tumban E, Peabody DS, Chackerian B. The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnology and Bioengineering. 111: 2398-406. PMID 24917327 DOI: 10.1002/Bit.25311 |
0.528 |
|
2014 |
Tyler M, Tumban E, Chackerian B. Second-generation prophylactic HPV vaccines: successes and challenges. Expert Review of Vaccines. 13: 247-55. PMID 24350614 DOI: 10.1586/14760584.2014.865523 |
0.475 |
|
2013 |
Tumban E, Peabody J, Peabody DS, Chackerian B. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine. 31: 4647-54. PMID 23933337 DOI: 10.1016/J.Vaccine.2013.07.052 |
0.499 |
|
2013 |
Tumban E, Maes NE, Schirtzinger EE, Young KI, Hanson CT, Whitehead SS, Hanley KA. Replacement of conserved or variable sequences of the mosquito-borne dengue virus 3' UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes. The Journal of General Virology. 94: 783-8. PMID 23255623 DOI: 10.1099/Vir.0.046664-0 |
0.581 |
|
2012 |
Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. Plos One. 7: e49751. PMID 23185426 DOI: 10.1371/Journal.Pone.0049751 |
0.543 |
|
2011 |
Tumban E, Peabody J, Peabody DS, Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. Plos One. 6: e23310. PMID 21858066 DOI: 10.1371/Journal.Pone.0023310 |
0.517 |
|
2011 |
Hunter Z, Tumban E, Dziduszko A, Chackerian B. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses. Vaccine. 29: 4584-92. PMID 21549786 DOI: 10.1016/J.Vaccine.2011.04.051 |
0.541 |
|
2011 |
Tumban E, Mitzel DN, Maes NE, Hanson CT, Whitehead SS, Hanley KA. Replacement of the 3' untranslated variable region of mosquito-borne dengue virus with that of tick-borne Langat virus does not alter vector specificity. The Journal of General Virology. 92: 841-8. PMID 21216984 DOI: 10.1099/Vir.0.026997-0 |
0.593 |
|
2006 |
Romero TA, Tumban E, Jun J, Lott WB, Hanley KA. Secondary structure of dengue virus type 4 3' untranslated region: impact of deletion and substitution mutations. The Journal of General Virology. 87: 3291-6. PMID 17030863 DOI: 10.1099/Vir.0.82182-0 |
0.546 |
|
Show low-probability matches. |